Prevalence of methylenetetrahydrofolate reductase C677T mutation among patients with acute ischemic cerebrovascular disease in Aragon;Prevalencia de la mutación C677T del gen de la metilentetrahidrofolato reductasa en pacientes con patología isquémica cerebrovascular aguda en la Comunidad Autónoma Aragonesa

Anales de Medicina Interna

Volumn 23, Issue 4, 2006, Pages 153-155

  Sanchez Marin B ^a   Grasa Ullrich, José María ^a,b,c   Torres, M ^a   Calvo, M T ^a   Martinez Jarreta B ^b   Garcia Erce J A ^a   Giralt, M ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c NONE   (Spain)

Author keywords

Folate; Homocystein; MTHFR; Stroke; Thrombofilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCREENING TEST; GENETICS; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; THROMBOPHILIA;

ADULT; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; THROMBOPHILIA;

EID: 33748172092     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
2. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000; 109: 870-4.
3. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-332.
4. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33: 51-6.
5. González Ordóñez AJ, Medina Rodríguez JM, Fernández Álvarez CR, Sánchez García J, Fernández Carreira JM, Álvarez Martínez MV, et al. Lowering high levels of fasting total homocysteine with folic acid and vitamins B in patients with venous thromboembolism: relationship between response and the C677T methylenetetrahydrofolate reductase (MTHFR) genotype. Med Clin (Barc) 2000; 114: 7-12.
6. Nowak-Göttl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-82.
7. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the japanese general population. Stroke 2003; 34: 1130-1135.
8. Yoo JH, Choi GD, Kang SS. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler Thromb Vasc Biol 2000; 20: 1921-5.
9. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31: 1069-75.
10. Cardo E, Monros E, Colome C, Artuch R, Campistol J, Pineda M, et al. Children with stroke: polymorphism of the MTHFR gene, mild hyperhomocysteinemia, and vitamin status. J Child Neurol 2000; 15: 295-8.
11. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-1843.
12. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201.
13. Smulders YM, de Man Am, Stehouwer CD, Slaats EH. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352: 1827-1828.
14. Yoo JH, Hong SB. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsivants. Metabolism 1999; 48: 1047-1051.
15. Ordón̂ez LA, Wurtman RJ. Folic acid deficiency and methyl group metabolism in rat brain: effects of L-dopa. Arch Biochem Biophys 1974; 160: 372-376.
16. Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Postdam study. Metabolism 2001; 50: 640-645.
17. Dekou V, Whincup P, Papacosta O, Ebrahim S, Lennon L, Ueland PM, et al. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. Atherosclerosis 2001; 154: 659-66.
18. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001; 47: 255-62.
19. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in the methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
20. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, et al. Dterminants ans vitamin responsiveness of intermediate hyperhomocysteinemia (< or = 40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996; 98: 2174-2183.
21. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokaosch G. Intermediate homocysteinemia: a thermolabile variant of the methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
22. Grasa JM, Torres M, Sánchez-Marín B, García-Erce JA, Calvo MT, Giralt M. Hiperhomocisteinemia y mutación C677T de la metilentetrahidrofolato reductasa. An Med Interna (Madrid) 2002; 19: 269.
23. Stern LL, Bagley PJ, Rosenberg IH, Selhub J. Conversion of 5-formyltetrahydrofolic acid to 5-methyltetrahydrofolic acid is unimpaired in folateadequate persons homozygous for the C677T mutation in the methylenetetrahydrofolate reductase gene. J Nutr 2000; 130: 2238-2242.
24. Nixon PF, Bertino JR. Effective absorption and utilization of oral formyltetrahydrofolate in man. N Engl J Med 1972; 286: 175-179.
25. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-1162.
26. Mayer O Jr, Äimon J, Bosolová H, Mromdka M, Äubrt I, Vobrubová J. The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. Eur J Clin Pharmacol 2002; 58: 1-5.